Browsing Category

64838 posts
Lifelong Learner Holdings announces the sale of PSI Services

Lifelong Learner Holdings announces the sale of PSI Services

LLH tightens strategic focus on Talogy, the expert talent management solutions provider. …
Relativity Announces Expansions to Relativity aiR, its Suite of Generative AI Solutions, at Legalweek 2024

Relativity Announces Expansions to Relativity aiR, its Suite of Generative AI Solutions, at Legalweek 2024

CHICAGO, Jan. 29, 2024 /PRNewswire/ — Relativity, a global legal technology company,…
OLIGHT Shines Bright at SHOT Show 2024: A Recap of Innovation and Super Customer Service

OLIGHT Shines Bright at SHOT Show 2024: A Recap of Innovation and Super Customer Service

LAS VEGAS, Jan. 29, 2024 /PRNewswire/ — OLIGHT, a leader in the portable…
AV-Comparatives Names Consumer Product of The Year in Summary Report 2023

AV-Comparatives Names Consumer Product of The Year in Summary Report 2023

INNSBRUCK, Austria, Jan. 29, 2024 /PRNewswire/ — AV-Comparatives awards Kaspersky as Product…
Lion's OTC Options Services Grows Significantly, Unlocking New Territory for Its Brokerage Business

Lion's OTC Options Services Grows Significantly, Unlocking New Territory for Its Brokerage Business

HONG KONG, Jan. 29, 2024 /PRNewswire/ — Lion Group Holding Ltd. ("Lion" or…
Vesicure Therapeutics made notable advancements using exosomes to target KRAS mutation

Vesicure Therapeutics made notable advancements using exosomes to target KRAS mutation

SUZHOU, China, Jan. 29, 2024 /PRNewswire/ — SiRNA technology offers distinct advantages over…
JETOUR T2 Debuts in the UAE, Featuring Advanced XWD Technology

JETOUR T2 Debuts in the UAE, Featuring Advanced XWD Technology

DUBAI, UAE, Jan. 29, 2024 /PRNewswire/ — On January 27th, 2024, JETOUR…
Oricell Announces FDA Clearance of IND Application for OriCAR-017, a novel GPRC5D Targeted CAR-T Cell Therapy Utilizing the Company's Proprietary Platform, for the Treatment of Relapsed/Refractory Multiple Myeloma.

Oricell Announces FDA Clearance of IND Application for OriCAR-017, a novel GPRC5D Targeted CAR-T Cell Therapy Utilizing the Company's Proprietary Platform, for the Treatment of Relapsed/Refractory Multiple Myeloma.

SHANGHAI and ROSELAND, N.J., Jan. 29, 2024 /PRNewswire/ — Oricell Therapeutics (Oricell),…